David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Nov

Today In Oncology

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care

Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?

Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer

In Case You Missed It: Roundup From ESMO Congress 2024

Exploring Issues in Oncofertility